Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $12.00 by Analysts at Bank of America

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective trimmed by Bank of America from $14.00 to $12.00 in a report released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday. Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Trading Down 2.2 %

YMAB stock opened at $4.85 on Wednesday. The stock has a 50-day moving average price of $6.46 and a two-hundred day moving average price of $10.62. The stock has a market cap of $217.23 million, a PE ratio of -8.98 and a beta of 0.65. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $18.19.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the company posted ($0.02) EPS. On average, analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently bought and sold shares of YMAB. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $267,000. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $133,000. Charles Schwab Investment Management Inc. lifted its stake in Y-mAbs Therapeutics by 9.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock valued at $3,676,000 after purchasing an additional 23,982 shares during the last quarter. FMR LLC lifted its stake in Y-mAbs Therapeutics by 23.1% in the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after purchasing an additional 6,822 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $44,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.